Abstract
The metabolic reduction of nabumetone was examined by inhibition and correlation studies using human liver microsomes and cytosol. This reduction was observed in both fractions, with the V max values for reduction activity being approximately fourfold higher, and the V max /K m values approximately three-fold higher, in the microsomes than in the cytosol. The reduction of nabumetone was inhibited by 18β-glycyrrhetinic acid, an 11β-hydroxysteroid dehydrogenase (11β-HSD) inhibitor, in the microsomal fraction. The reduction activity was also inhibited by quercetin and menadione [carbonyl reductase (CBR) inhibitors], and by phenolphthalein and medroxyprogesterone acetate [potent inhibitors of aldo–keto reductase (AKR) 1C1, 1C2 and 1C4] in the cytosol. A good correlation (r 2 = 0.93) was observed between the reduction of nabumetone and of cortisone, as a marker of 11β-HSD activity, in the microsomal fractions. There was also an excellent relationship between reduction of nabumetone and of the AKR1C substrates, acetohexamide, and ethacrynic acid (r 2 = 0.92 and 0.93, respectively), in the cytosol fractions. However, a poor correlation was observed between the formation of 4-(6-methoxy-2-naphthyl)-butan-2-ol (MNBO) from nabumetone and CBR activity (with 4-benzoyl pyridine reduction as a CBR substrate) in the cytosol fractions (r 2 = 0.24). These findings indicate that nabumetone may be metabolized by 11β-HSD in human liver microsomes, and primarily by AKR1C4 in human liver cytosol, although multiple enzymes in the AKR1C subfamily may be involved. It cannot be completely denied that CBR is involved to some extent in the formation of MNBO from nabumetone in the cytosol fraction.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Atalla A, Maser E (2001) Characterization of enzymes participating in carbonyl reduction of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in human placenta. Chem Biol Interact 130–132:737–748
Atalla A, Breyer-Pfaff U, Maser E (2000) Purification and characterization of oxidoreductases-catalyzing carbonyl reduction of the tobacco-specific nitrosamine 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human liver cytosol. Xenobiotica 30:755–769
Barski OA, Tipparaju SM, Bhatnagar A (2008) The aldo–keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev 40:553–624
Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, Withopf B, Wagner K (2010) The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos 38:667–678
Davies NM (1997) Clinical pharmacokinetics of nabumetone. The dawn of selective cyclo-oxygenase-2 inhibition? Clin Pharmacokinet 33:404–416
Deyashiki Y, Taniguchi H, Amano T, Nakayama T, Hara A, Sawada H (1992) Structural and functional comparison of two human liver dihydrodiol dehydrogenases associated with 3α-hydroxysteroid dehydrogenase activity. Biochem J 282:741–746
Diederich S, Grossmann C, Hanke B, Quinkler M, Herrmann M, Bähr V, Oelkers W (2000) In the search for specific inhibitors of human 11β-hydroxysteroid-dehydrogenases (11β-HSDs): chenodeoxycholic acid selectively inhibits 11β-HSD-I. Eur J Endocrinol 142:200–207
Friedel HA, Todd PA (1988) Nabumetone. A preliminary review of pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatic diseases. Drugs 35:504–524
Friedel HA, Langtry HD, Buckley MM (1993) Nabumetone. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases. Drugs 45:131–156
Grothusen A, Hardt J, Bräutigam L, Lang D, Böcker R (1996) A convenient method to discriminate between cytochrome P450 enzymes and flavin-containing monooxygenases in human liver microsomes. Arch Toxicol 71:64–71
Haddock RE, Jeffery DJ, Lloyd JA, Thawley AR (1984) Metabolism of nabumetone (BRL 14777) by various species including man. Xenobiotica 14:327–337
Hara A, Taniguchi H, Nakayama T, Sawada H (1990) Purification and properties of multiple forms of dihydrodiol dehydrogenase from human liver. J Biochem 108:250–254
Higaki Y, Usami N, Shintani S, Ishikura S, El-Kabbani O, Hara A (2003) Selective and potent inhibitors of human 20α-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone. Chem Biol Interact 143–144:503–513
Imamura Y, Shimada H (2004) Strain- and sex-related differences of carbonyl reductase activities in kidney microsomes and cytosol of rats. J Appl Toxicol 24:437–441
Kendall MJ, Chellingsworth MC, Jubb R, Thawley AR, Undre NA, Kill DC (1989) A pharmacokinetic study of the active metabolite of nabumetone in young healthy subjects and older arthritis patients. Eur J Clin Pharmacol 36:299–305
Kobylinska K, Barlinska M, Kobylinska M (2003) Analysis of nabumetone in human plasma by HPLC. Application to single dose pharmacokinetic studies. J Pharm Biomed Anal 32:323–328
Lee SK, Kim JH, Seo YM, Kim HC, Kang MJ, Jeong HG, Lee ES, Jeong TC (2008) In vitro characterization of the enzymes involved in the metabolism of 1-furan-2-yl-3-pyridin-2-yl-propenone, an anti-inflammatory propenone compound. Arch Pharm Res 31:764–770
Mangan FR, Flack JD, Jackson D (1987) Preclinical overview of nabumetone. Pharmacology, bioavailability, metabolism, and toxicology. Am J Med 83:6–10
Maser E, Stinner B, Atalla A (2000) Carbonyl reduction of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) by cytosolic enzymes in human liver and lung. Cancer Lett 148:134–144
Maser E, Friebertshäuser J, Völker B (2003) Purification, characterization and NNK carbonyl reductase activities of 11β-hydroxysteroid dehydrogenase type 1 from human liver: enzyme cooperativity and significance in the detoxification of a tobacco-derived carcinogen. Chem Biol Interact 143–144:435–448
Matsumoto K, Nemoto E, Hasegawa T, Akimoto M, Sugibayashi K (2011a) In vitro characterization of the cytochrome P450 isoforms involved in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone. Biol Pharm Bull 34:734–739
Matsumoto K, Hasegawa T, Akimoto M, Sugibayashi K (2011b) Reductive metabolism of nabumetone, an anti-inflammatory drug. Abstracts vol. IV, The 131rd annual meeting of the pharmaceutical society of Japan, Shizuoka, 28–31 March 2011, p 219
Matsunaga T, Shintani S, Hara A (2006) Multiplicity of mammalian reductases for xenobiotic carbonyl compounds. Drug Mtab Pharmacokinet 21:1–18
Mikami E, Goto T, Ohno T, Matsumoto H, Nishida M (2000) Simultaneous analysis of naproxen, nabumetone and its major metabolite 6-methoxy-2-naphthylacetic acid in pharmaceuticals and human urine by high-performance liquid chromatography. J Pharm Biomed Anal 23:917–925
Nakayama T, Hara A, Yashiro K, Sawada H (1985) Reductase for carbonyl compounds in human liver. Biochem Pharmacol 34:107–117
Nobilis M, Kopecký J, Kvetina J, Svoboda Z, Pour M, Kunes J, Holcapek M, Kolárová L (2003) Comparative biotransformation and disposition studies of nabumetone in humans and minipigs using highperformance liquid chromatography with ultraviolet, fluorescence and mass spectrometric detection. J Pharm Biomed Anal 32:641–656
Ohara H, Miyabe Y, Deyashiki Y, Matsuura K, Hara A (1995) Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver. Biochem Pharmacol 50:221–227
Ohtani I, Kusumi T, Kashman Y, Kakisawa H (1991) High-field FT NMR application of Mosher’s method. The absolute configurations of marine terpenoids. J Am Chem Soc 113:4092–4096
Penning TM, Burczynski ME, Jez JM, Hung CF, Lin HK, Ma H, Moore M, Palackal N, Ratnam K (2000) Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo–keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 351:67–77
Piwowarska J, Wrzosek M, Radziwoń-Zaleska M, Ryszewska-Pokraśniewicz B, Skalski M, Matsumoto H, Biernacka-Bazyluk A, Szelenberger W, Pachecka J (2009) Serum cortisol concentration in patients with major depression after treatment with clomipramine. Pharmacol Rep 61:604–611
Skarydova L, Nobilis M, Wsól V (2013) Role of carbonyl reducing enzymes in the phase I biotransformation of the non-steroidal anti-inflammatory drug nabumetone in vitro. Xenobiotica 43:346–354
Steckelbroeck S, Oyesanmi B, Jin Y, Lee SH, Kloosterboer HJ, Penning TM (2006) Tibolone metabolism in human liver is catalyzed by 3α/3β-hydroxysteroid dehydrogenase activities of the four isoforms of the aldo–keto reductase (AKR)1C subfamily. J Pharmacol Exp Ther 316:1300–1309
Tani N, Yabuki M, Komuro S, Kanamaru H (2005) Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride. Xenobiotica 35:1121–1133
Tong Z, Chandrasekaran A, Li H, Rotshteyn Y, Erve JC, Demaio W, Talaat R, Hultin T, Scatina J (2010) In vitro metabolism and identification of human enzymes involved in the metabolism of methylnaltrexone. Drug Metab Dispos 38:801–807
Tsuchiya S, Ishibashi K, Asano H, Hirano K, Noguchi H (1988) Pharmacokinetics of nabumetone and its metabolic pathways in rats. Xenobio Metab Dispos 3:67–74
Turpeinen M, Hofmann U, Klein K, Mürdter T, Schwab M, Zanger UM (2009) A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes. Drug Metab Dispos 37:1017–1024
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Matsumoto, K., Hasegawa, T., Kamei, T. et al. Reductive metabolism of nabumetone by human liver microsomal and cytosolic fractions: exploratory prediction using inhibitors and substrates as marker probes. Eur J Drug Metab Pharmacokinet 40, 127–135 (2015). https://doi.org/10.1007/s13318-014-0190-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13318-014-0190-0